Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Employment agrmnt
Asset disposition
Director departure
Quarterly results
Auditor change
Acq. announced
Consulting agrmnt
Appointed director
Inv. presentation
|
|
LISATA THERAPEUTICS, INC. (CLBS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/14/2023 |
8-K
| Quarterly results |
| 05/09/2023 |
8-K
| Quarterly results |
| 11/10/2022 |
8-K
| Quarterly results |
| 08/05/2022 |
8-K
| Quarterly results |
| 05/05/2022 |
8-K
| Quarterly results |
| 11/04/2021 |
8-K
| Quarterly results |
| 08/05/2021 |
8-K
| Quarterly results |
| 05/06/2021 |
8-K
| Quarterly results |
| 11/05/2020 |
8-K
| Quarterly results, Appointed a new director |
| 08/13/2020 |
8-K
| Quarterly results |
| 05/07/2020 |
8-K
| Quarterly results |
| 05/09/2019 |
8-K
| Quarterly results |
| 11/08/2018 |
8-K
| Quarterly results|
Docs:
|
"Caladrius Biosciences Reports 2018 Third Quarter Financial Results Development programs remain on track accompanied by continued strong fiscal management Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. - Caladrius Biosciences, Inc. , a late-stage therapeutics development biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune disease, announces financial results for the three ended September 30, 2018, and provides a business update. Highlights of the 2018 third quarter and early fourth quarter include:",
"Caladrius Biosciences Appoints Cynthia Schwalm to Board of Directors BASKING RIDGE, N.J. - Caladrius Biosciences, Inc. , a late-stage therapeutics development biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune disease, announces today the appointment of Ms. Cynthia Schwalm to its Board of Directors. “Cynthia brings extensive experience in leading and managing biopharmaceutical companies during transformative years of growth,” said David J. Mazzo, PhD, Chief Executive Officer of Caladrius. “We are delighted with her addition to our board and believe she will provide a fresh perspective while making important contributions to our progress, particularly when it comes to commercialization. We look forward to her guidance as w..." |
|
| 05/10/2018 |
8-K
| Quarterly results |
| 11/09/2017 |
8-K
| Quarterly results|
Docs:
|
"Caladrius Biosciences Reports 2017 Third Quarter Results Conference call begins today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., - Caladrius Biosciences, Inc. , a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications, announces results for the three and nine months ended September 30, 2017. Highlights of the 2017 third quarter and recent weeks include: • Enrolled the 70 th subject in The Sanford Project: T-Rex Study , a prospective, randomized, placebo-controlled, double-blind Phase 2 clinical trial to evaluate the safety and efficacy of CLBS03 as a treatment for recent-onset type 1 diabetes , which triggered a $2.4 million milestone payment and the delivery of 508,475 shares of Caladrius common stock as pe..." |
|
| 08/10/2017 |
8-K
| Quarterly results |
| 11/07/2016 |
8-K
| Quarterly results |
| 08/09/2016 |
8-K
| Quarterly results |
| 11/12/2013 |
8-K
| Quarterly results |
|
|